GT Biopharma, Inc. GTBP
5.27 USD +0.14 (+2.73%)
At closeNov 3, 2026, 4:04 PM EST
5.27 0.00 0.00%
After hours · Nov 3, 4:04 PM ET
5.05 Day range 5.32
4.91 52-week range 28.75
- YTD
- +571.34%
- 1 year
- +745.91%
News
globenewswire.com GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting SAN FRANCISCO, CALIFORNIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Pomdoctor (NASDAQ:POM) stock moved upwards by 115.1% to $1.43 during Wednesday's regular session. The market value of their outstanding shares is at $4.9 million. Stablecoin Development…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers PDS Biotechnology (NASDAQ:PDSB) shares rose 63.7% to $0.65 during Tuesday's regular session. The market value of their outstanding shares is at $22.3 million. DataMEDS AI (NASDAQ:MEDS) shares…
globenewswire.com GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma FDA clearance of a new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored trial (IST) protocol Initiation of Phase 1 trial in MM patients contingent upon timing and receipt of…
benzinga.com EXCLUSIVE: GT Biopharma Announces Potential New Indication for GTB-5550, A B7-H3-Targeted Natural Killer Cell Engager, For Multiple Myeloma; FDA Clearance Under Investigator Sponsored Trial Protocol FDA clearance of a new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored trial (IST) protocolInitiation of Phase 1 trial in MM patients contingent upon timing and receipt of…
benzinga.com EXCLUSIVE: GT Biopharma Achieves Development Milestone for Human Trial for Novel Blood Cancer Therapy GT Biopharma secures FDA IND clearance for GTB-5550, advancing its TriKE therapy into Phase 1 clinical trials for multiple myeloma.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Basel Medical Group (NASDAQ:BMGL) shares moved upwards by 59.8% to $7.32 during Monday's regular session. Scinai Immunotherapeutics (NASDAQ:SCNI) stock increased by 45.18% to $2.41. The…
seekingalpha.com GT Biopharma, Inc. (GTBP) Discusses TriKE Platform, Clinical Progress, and the Case for NK Cell Immunotherapy Transcript GT Biopharma, Inc. (GTBP) Discusses TriKE Platform, Clinical Progress, and the Case for NK Cell Immunotherapy Transcript- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares increased by 110.6% to $1.39 during Friday's regular session. Tenon Medical (NASDAQ:TNON) shares rose 69.71% to $8.99. The company's market cap…
globenewswire.com GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026 SAN FRANCISCO, CALIFORNIA, Sept. 11, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers iSpecimen (NASDAQ:ISPC) shares increased by 10.4% to $1.7 during Friday's after-market session. The market value of their outstanding shares is at $3.8 million. Genelux (NASDAQ:GNLX) stock…
benzinga.com GT Biopharma Q2 EPS $(0.12) Misses $(0.08) Estimate GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.08) by 50 percent. This is a 78.18 percent increase over losses of $(0.55)…
globenewswire.com GT Biopharma Reports Second Quarter 2026 Financial Results Phase 1 trial evaluating GTB-3650 TriKE ® remains ongoing, with an update anticipated in 2H 2026
globenewswire.com Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet Issued on behalf of GT Biopharma, Inc. (Nasdaq: GTBP) A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid…- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
globenewswire.com GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives Increased integration of artificial intelligence–based tools across the discovery and engineering of tumor-targeting engagers and multi-domain proteins to accelerate development while reducing…
benzinga.com EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout GT Biopharma says AI-driven drug discovery tools are accelerating pipeline development and may yield new pre-IND candidates by 2027.
prnewswire.com The $13 Million Company Teaching the Immune System to Hunt Cancer /PRNewswire/ -- USA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ: GTBP)- benzinga.com Nasdaq Grants GT Biopharma Additional 180 Days To Regain Compliance https://www.sec.gov/ix?doc=/Archives/edgar/data/109657/000149315226024913/form8-k.htm
prnewswire.com B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic /PRNewswire/ -- USA News Group News Commentary - For more than two decades, B7-H3 sat on the shortlist of theoretically perfect cancer drug targets that nobody
benzinga.com GT Biopharma Q1 EPS $(0.11) Misses $(0.08) Estimate GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.08) by 37.5 percent. This is a 66.67 percent increase over losses of…
globenewswire.com GT Biopharma Reports First Quarter 2026 Financial Results Phase 1 trial evaluating GTB-3650 TriKE ® remains ongoing, with additional updates anticipated in 2H 2026 Phase 1 basket trial evaluating GTB-5550 TriKE ® in multiple solid tumor types known to…- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
globenewswire.com GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors GTB-5550 is now the 3rd TriKE ® to enter the clinic and an expansion into a broader solid tumor opportunity, with the Phase 1 trial likely to focus on prostate cancer patients during the dose…
benzinga.com EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types GT Biopharma Inc. (NASDAQ:GTBP) on Thursday dosed the first patient on a Phase 1 dose-escalation basket trial evaluating GTB-5550, its B7-H3-targeted NK cell engager for solid tumors expressing B7-H3.
benzinga.com EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types GT Biopharma doses first patient in Phase 1 GTB-5550 trial targeting B7-H3-positive solid tumors with subcutaneous TriKE therapy.- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
defenseworld.net Head to Head Contrast: Cogent Biosciences (NASDAQ:COGT) versus GT Biopharma (NASDAQ:GTBP) Cogent Biosciences (NASDAQ: COGT - Get Free Report) and GT Biopharma (NASDAQ: GTBP - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies…
zacks.com GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should Know GT Biopharma (GTBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com GT Biopharma (GTBP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? GT Biopharma (GTBP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean…
globenewswire.com GT Biopharma to Participate in the 38th Annual Roth Conference SAN FRANCISCO, CALIFORNIA, March 11, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics…- benzinga.com GT Biopharma Q4 EPS $(4.84) Down From $(1.66) YoY GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(4.84) per share. This is a 191.57 percent decrease over losses of $(1.66) per share from the same period last year.
benzinga.com GT Biopharma Reported FY25 Net Loss Of $28.4M, Cash Balance Of ~$9M To Fund Operations Through The Fourth Quarter Of 2026 Year Ended December 31, 2025 Financial SummaryCash Position: The Company had cash and cash equivalents of approximately $7 million as of December 31, 2025, and an unaudited proforma cash balance as…
globenewswire.com GT Biopharma Reports Full Year 2025 Financial Results Phase 1 trial evaluating GTB-3650 TriKE ® continues to actively enroll, with the next update anticipated in Q3 2026 following completion of enrollment in dose Cohort 5
globenewswire.com GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference SAN FRANCISCO, CALIFORNIA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics…- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com GT Biopharma Receives FDA Clearance Of Investigational New Drug Application For GTB-5550 TriKE GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026Phase 1 protocol allows multiple solid tumor types known to express B7-H3Unaudited proforma cash balance as of January 31,…
globenewswire.com GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3 GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026 Phase 1 protocol allows multiple solid tumor types known to express B7-H3 Unaudited proforma cash balance as of January 31,…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
globenewswire.com GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers GT Biopharma targets a portion of the estimated $362 billion global solid tumor market Preliminary, unaudited cash balance of approximately $7 million as of December 31, 2025 anticipated to extend…
benzinga.com EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment GT Biopharma submitted an IND application for GTB-5550 TriKE for solid tumors. Phase 1 trial planned for 2026.- benzinga.com EXCLUSIVE: GT Biopharma Announces IND Submission For GTB-5550 TriKE; Reports Preliminary Unaudited Cash Balance Of ~$7M As Of Dec. 31, 2025 GT Biopharma targets a portion of the estimated $362 billion global solid tumor market with its B7-H3 TrikePreliminary, unaudited cash balance of approximately $7 million as of December 31, 2025…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com GT Biopharma Advances Potent NK-Cell Therapies As GTB 3650, Is Currently Being Tested In Phase 1 Trials For Patients With Relapsed Or Refractory Acute Myeloid Leukemia Within this landscape, GT Biopharma (NASDAQ:GTBP) is advancing a proprietary platform designed to harness NK cells against cancer. Its main candidate, GTB 3650, is currently being tested in Phase 1…